Heart disease is the leading cause of death in the U.S. and other parts of the world. A major contributing factor is atherosclerosis (hardening of the arteries), but a new treatment may be on the way.
At the Center for Metabolomics and Bioanalysis in Madrid, Spain, Dr. Coral Barbas recently discovered metabolic markers that may change the way we treat atherosclerosis. More research is necessary, but her discovery indicates that atherosclerosis patients who are additionally treated for insulin resistance may achieve better results.
Metabolites, genes and proteins can provide important clues about disease states and potential treatments. The science of metabolomics gives us critical insights into diabetes, heart disease and other life-threatening conditions.
The Madrid center is equipped with a suite of instruments from Agilent, including LC/MS, GC/MS and CE/MS systems. “There are a lot of challenges in every step of the workflow, and Agilent is able to help in many, many ways,” Dr. Barbas says.
This information is for research purposes only. It is not intended for any use in diagnostic procedures.
For more information go to: